Kevin Peacock currently serves as AVEO’s Senior Vice President of Marketing. Prior to joining AVEO, he served as both the Vice President, New Product Planning and Business Development at Lycera where he was leading the early commercialization process for Lycera’s novel immune-oncology compounds and in 2015 completed an exclusive strategic collaboration and license with Celgene resulting in $100M in non-dilutive financing. Mr. Peacock also previously served as Vice President, Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge® in select European countries and managed the US Business Analytics team. Mr. Peacock was Senior Director and Product Champion for Savient Pharmaceuticals while working on Krystexxa® and previously served as Senior Director of New Product Planning at Allos Therapeutics. Prior to that, Mr. Peacock held various roles on the ERBITUX® brand team while at ImClone Systems. Mr. Peacock’s has extensive experience in the oncology commercialization process including marketing, market research, new product planning and product development on the R&D side. Mr. Peacock earned his Bachelor of Administration in Finance and Risk Management from Temple University.
Greg Oehrtman brings over 20 years of Drug Development experience to his role returning to AVEO after 8 years. Dr. Oehrtman has held roles of increasing seniority in Drug Development and Manufacturing at Quintiles/Catalent, Amylin, Stealth Biotherapeutics, and Dicerna. He has led both drug substance and product development and manufacturing from early pre-clinical to commercial validations, supporting development of Fast Acting Advil, Advil PM, Bydureon, FOTIVDA, Elamipretide, and Nedosiran. While in these roles, he has managed product development of small molecules, peptides, and antibodies as oral and sterile injectable along with combination device development. Dr. Oehrtman received his Ph.D in Chemical Engineering from Massachusetts Institute of Technology.
Mr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations. He has over 20 years of commercial pharmaceutical and biotechnology experience, including 15 years developing and commercializing oncology products. At AVEO, in addition to developing the Company’s commercial strategy and infrastructure, Mr. Ferraresso has played a key role in business development activities, including the Company’s immuno-oncology clinical collaborations and the over $400 million agreement amendment with Kyowa Kirin for non-oncology rights to tivozanib in AVEO’s territories. Prior to joining AVEO, he served in sales and commercial operations roles of increasing responsibility at several biotechnology and pharmaceutical companies, including at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics, and Muro Pharmaceuticals. Mr. Ferraresso has extensive experience in commercial strategy including partnerships, development, pricing, and field deployment models and has launched Oprapred™, Plenaxis™, Zyflo™ and Feraheme™. Mr. Ferraresso holds a BA degree in Economics from Assumption College.